Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSPE.L Regulatory News (SPE)

  • There is currently no data for SPE

Trading Update

18 Jan 2005 07:00

Embargoed Release: 07:00hrs Tuesday 18 January 2005 SOPHEON PLC (`Sopheon' or `the Company') TRADING UPDATE Sopheon plc, the international provider of solutions that improve the returnfrom innovation and product development, announces that the Company's EBITDAresult for the final quarter of 2004 is expected to be positive, and that theconsolidated annual EBITDA loss for 2004 is expected to be in line with brokerforecasts of ‚£1.15m (2003 - ‚£4.07m). Sales growth over the prior year achievedin Sopheon's continuing software business is substantial, however, totalreported revenues for 2004 are expected to be moderately below brokerforecasts. This expectation is due in part to the weakness in the dollar duringthe later stages of the year. Nevertheless the overall effect of the weakdollar is expected to have been marginally positive, due to the fact that alarge portion of Sopheon's costs are dollar denominated.As indicated in earlier announcements, the final quarter performance wasdependent on completion of major sales in December. Sopheon was successful insigning three such orders. Each customer is a global leader in its respectiveindustry and a widely recognized name, and two of the transactions includedlicense fees of around $600,000. Apart from their financial and brand value,these deals underpin Sopheon's credentials in two industries with significantidentified potential: fast-moving consumer goods (FMCG) and financial services.Several other transactions were concluded during the quarter, primarily in thechemicals sector, where we already have a substantial base of customers. Wecontinue to focus on pipeline creation and extending business with existingcustomers. An excellent example of the latter is BASF. Developed as a customerthrough one of Sopheon's distribution partners, BASF began implementation ofAccolade a year ago. Our relationship with this chemicals industry leader hasgrown rapidly since then, and BASF is now one of four Sopheon clients that havecontracted for 2000 or more Accolade seat-licenses.Sopheon made important progress in 2004 in positioning itself for the longerterm by securing partnerships on two fronts: strategic alliances in keymarkets, and distribution partners in geographical areas outside the Company'sexisting sphere of operations. As a result of this effort we are part ofMicrosoft's Collaborative Product Development initiative. Since announcement ofthe program in October, Microsoft and Sopheon have been working together toenhance and promote the integration of their technologies. To enabledevelopment efforts arising from this and other initiatives, and with supportfrom Microsoft, Sopheon implemented a controlled expansion in R&D resources,recruiting into our Denver development center. During the year Sopheon alsoundertook a successful balance sheet restructuring, and continues to haveaccess to the group's ¢â€š¬10m equity line, of which over 90% remains untapped.Financial expectations noted above are subject to the completion of theyear-end financial close process. Consistent with prior years, Sopheon plans toissue its 2004 preliminary results around the end of March.Sopheon's Chairman, Barry Mence said:"Achieving a positive quarterly result is an important milestone for Sopheon.We are focused on the challenge of maintaining this momentum into the firsthalf of 2005, encouraged by our recent successes and the opportunities that arebuilding through our strategic relationships."For further information contact:Barry Mence, Chairman Sopheon plc Tel : + 44 (0) 1483 685 735 Arif Karimjee, CFO Adam Reynolds Hansard Communications Tel : + 44 (0) 207 245 1100 Andrew Tan + 44 (0) 7957 203 685 Barbara Jansen Citigate First Financial Tel : + 31 (0) 205 754 010About SopheonSopheon (LSE:SPE) is an international provider of software and services thathelp organizations improve the business impact of product development. TheSopheon Accolade‚® product development system automates gate- or phase-basedproduct development (PD) processes and provides strategic decision support thatallows companies to improve innovation, cut product development spending wasteand shorten time to market. Sopheon is listed on the AIM market of the LondonStock Exchange and on the Euronext in the Netherlands. For more information,please visit www.sopheon.com.END
Date   Source Headline
30th Jan 201810:27 amRNSIssue of Equity
29th Jan 20187:00 amRNSTrading Update
4th Jan 20182:05 pmRNSSecond Price Monitoring Extn
4th Jan 20182:00 pmRNSPrice Monitoring Extension
4th Jan 20187:00 amRNSTrading Update
22nd Dec 20171:01 pmRNSHolding(s) in Company
22nd Dec 201712:37 pmRNSConversion of Loan Stock
8th Dec 20177:00 amRNSAmendment to the Terms of Convertible Loan Stock
9th Nov 20177:00 amRNSCertis Europe Partners with Sopheon
19th Oct 20177:00 amRNSSopheon Funding Award
11th Oct 201710:44 amRNSDirector/PDMR Shareholding
2nd Oct 20177:00 amRNSIssue of Equity
26th Sep 20177:00 amRNSSopheon "Leader" in Strategic Portfolio Management
5th Sep 20177:00 amRNSSopheon's Accolade Software beyond innovation
24th Aug 20177:00 amRNSHalf Yearly Report
21st Jul 201710:32 amRNSDirector Shareholdings
6th Jul 20177:00 amRNSAccolade Release 11.2
29th Jun 20177:00 amRNSNew Approach to Product Development with Accolade
13th Jun 201712:04 pmRNSDirector Shareholdings
8th Jun 201712:09 pmRNSResult of AGM
8th Jun 20177:00 amRNSAGM Statement
26th May 20174:33 pmRNSIssue of Equity
26th Apr 20173:50 pmRNSIssue of Equity
12th Apr 201712:01 pmRNSIssue of Equity
7th Apr 20171:37 pmRNSDirector Shareholdings
31st Mar 20177:00 amRNSDirector Shareholdings
31st Mar 20177:00 amRNSIssue of Equity
23rd Mar 20177:00 amRNSFinal Results
23rd Feb 20177:00 amRNSAccolade Release 11.1
16th Feb 20177:00 amRNSGrant of Options / PDMR dealing
30th Jan 20177:00 amRNSTrading Update
21st Nov 201611:50 amRNSIssue of Equity
3rd Nov 20168:00 amRNSAccolade Release 11.0
29th Sep 201612:41 pmRNSIssue of Equity
22nd Sep 20169:09 amRNSIssue of Equity
15th Sep 20163:09 pmRNSIssue of Equity
25th Aug 20167:00 amRNSHalf Yearly Report
28th Jul 20165:01 pmRNSHolding(s) in Company
26th Jul 201610:49 amRNSHolding(s) in Company
12th Jul 201610:48 amRNSHolding(s) in Company
29th Jun 20165:32 pmRNSDirector Dealing
16th Jun 20164:22 pmRNSDirector Dealing
14th Jun 20164:18 pmRNSDirector Dealing
10th Jun 20162:13 pmRNSDirector Dealing
9th Jun 201611:37 amRNSResult of AGM
9th Jun 20167:00 amRNSAGM Statement
31st May 20163:09 pmRNSIssue of Equity
5th May 20161:25 pmRNSHolding(s) in Company
4th May 20167:00 amRNSAccolade Release 10.3
3rd May 20161:27 pmRNSDirector Shareholdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.